Nosopharm SAS
https://www.nosopharm.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nosopharm SAS
Tech Transfer Roundup: Lysogene Elects Option On Gene Therapy Discovered At Weizmann Institute
French biotech brings candidate for Gaucher and Parkinson’s disease in-house under 2020 pact with Weizmann. Cellevolve, Seattle Children’s partner on cell therapies for CNS cancers.
Evotec Takes The Lead On EU-Backed Antibiotic R&D Project
The 11-member GNA NOW alliance aims to move a treatment for some of the most threatening drug-resistant bacteria through early-phase development by 2024 using a mix of public and private funds.
Deal Watch: Genentech Inks New Collaborations With Skyhawk, Convelo
Skyhawk continues its recent spate of deal-making, using its SkyStar platform in a deal with Genentech, which also is looking into neurology with Convelo. AbbVie buys STING specialist Mavupharma, while Recordati pays Novartis $390m for Cushing’s products.
New Antibiotic Class Is Aim Of Evotec R&D Pact With Nosopharm
Evotec and Nosopharm plan to develop and then test in humans the first novel antibiotic class for fighting Gram-negative Enterobacteriaceae infections in 40 years
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice